title: Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system.
authors: Division of Hematology-Oncology, Department of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
authors: Christopher
authors: C
authors: Larson
authors: Natalie
authors: N
authors: Mendez
authors: Tony
authors: T
authors: Reid
mesh_terms: D018076:DNA, Complementary; D005260:Female; D016158:Genes, p53; D006801:Humans; D008297:Male; D053758:Nanoparticles; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*
chemical_list: D018076:DNA, Complementary
references: Mol Cancer Ther. 2002 Mar;1(5):337-46
references: 12489850
references: Nucleic Acids Res. 2004 Mar 16;32(5):e48
references: 15026537
references: Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a001016
references: 20300207
references: Br J Cancer. 2005 Feb 14;92(3):434-44
references: 15668707
references: Clin Immunol. 2006 Nov;121(2):144-58
references: 16904380
references: Hum Gene Ther. 2002 Feb 10;13(3):469-81
references: 11860713
references: Curr Drug Metab. 2002 Feb;3(1):39-59
references: 11878310
references: J Cancer Res Clin Oncol. 1996;122(6):360-5
references: 8642047
references: Pharm Res. 2002 Nov;19(11):1599-605
references: 12458664
references: Hum Gene Ther. 1997 Jan 20;8(2):177-85
references: 9017421
references: Nature. 2011 Aug 31;477(7362):99-102
references: 21886163
references: J Clin Oncol. 2005 Oct 20;23(30):7395-6
references: 16186590
references: J Control Release. 2001 Jul 6;74(1-3):115-28
references: 11489488
references: Mol Ther. 2012 Jul;20(7):1298-304
references: 22525514
references: Mol Ther. 2013 May;21(5):1096-103
references: 23609015